Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Zai Lab's Niraparib Shows 3X Longer PFS Compared to Placebo In Ovarian Cancer

Zai Lab Limited (NASDAQ:ZLABpresented data from the Phase 3 PRIME study of Zejula (niraparib) as maintenance therapy in Chinese ovarian cancer patients.

  • Zejula demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) with a tolerable safety profile with newly diagnosed ovarian cancer following response to platinum-based chemotherapy, regardless of biomarker status.
  • The median Progression-free survival (PFS) was significantly longer for patients treated with niraparib than placebo: 24.8 months versus 8.3 months.
  • Overall survival data are still immature (percentage of death in niraparib and placebo groups are 14.5% vs. 21.7%); there is a trend in favor of niraparib at the data cut-off.
  • The safety profile of niraparib was improved with the individualized starting dosing (ISD) prospectively applied to all patients. 
  • In December 2021, the National Reimbursement Drug List (NRDL) released by China's National Healthcare Security Administration (NHSA) was updated to include Zejula as a first-line maintenance treatment of ovarian cancer.
  • Price Action: ZLAB shares traded lower by 1.63% at $38.10 on the last check Monday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.